GlassScriptPhysician profile
Sonia Sharma
NPI 1669737664
$1,891.73
in general payments reported to CMS, 2019-2025
22 companies · $675 in 2025
The $675 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $174 · 2023: $361 · 2024: $367 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.80 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $327.38 | 2019-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $291.31 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $240.77 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Currax Pharmaceuticals LLC | $193.21 | 2023-2025 | Contrave, Nexletol |
| Pfizer INC. | $160.58 | 2019-2020 | |
| Abbvie INC. | $134.86 | 2023-2025 | Vraylar |
| Inspire Medical Systems, INC. | $118.51 | 2023 | Inspire |
| Exact Sciences Corporation | $65.73 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $38.80 | 2020 | |
| Madrigal Pharmaceuticals | $35.58 | 2025 | Rezdiffra |
| Mylan Specialty L.P. | $34.09 | 2019 | |
| Allergan, INC. | $33.70 | 2020 | |
| Janssen Pharmaceuticals, INC | $30.42 | 2024 | Spravato |
| Glaxosmithkline, LLC. | $30.17 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $29.95 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $29.54 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.52 | 2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $19.62 | 2024 | Voquezna |
| Neos Therapeutics, LP | $16.32 | 2020 | |
| Amarin Pharma, INC. | $13.38 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.